Evidence map›Paper›PMID 42252579›Full record

ArticleJournal of cellular and molecular medicine2026

Deferoxamine Improves Radiation-Induced Peripheral Neuropathy.

Christopher V Lavin, Alexander Z Fazilat, Carter B Kendig, Palca Shibale, Kelly X Huang, Sriya Nemani, Jennifer B Parker, Caleb Valencia, Naga A R Ailury, Michelle Griffin and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cellular and molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Christopher V LavinHagey Laboratory for Pediatric Regenerative Medicine, Stanford University School of Medicine, Stanford, California, USA.
Alexander Z FazilatHagey Laboratory for Pediatric Regenerative Medicine, Stanford University School of Medicine, Stanford, California, USA.
Carter B KendigHagey Laboratory for Pediatric Regenerative Medicine, Stanford University School of Medicine, Stanford, California, USA.
Palca ShibaleHagey Laboratory for Pediatric Regenerative Medicine, Stanford University School of Medicine, Stanford, California, USA.
Kelly X HuangHagey Laboratory for Pediatric Regenerative Medicine, Stanford University School of Medicine, Stanford, California, USA.
Sriya NemaniHagey Laboratory for Pediatric Regenerative Medicine, Stanford University School of Medicine, Stanford, California, USA.
Jennifer B ParkerHagey Laboratory for Pediatric Regenerative Medicine, Stanford University School of Medicine, Stanford, California, USA.
Caleb ValenciaHagey Laboratory for Pediatric Regenerative Medicine, Stanford University School of Medicine, Stanford, California, USA.
Naga A R AiluryHagey Laboratory for Pediatric Regenerative Medicine, Stanford University School of Medicine, Stanford, California, USA.
Michelle GriffinHagey Laboratory for Pediatric Regenerative Medicine, Stanford University School of Medicine, Stanford, California, USA.
Arash MomeniHagey Laboratory for Pediatric Regenerative Medicine, Stanford University School of Medicine, Stanford, California, USA.ORCID 0000-0002-6452-751X
Michael T LongakerHagey Laboratory for Pediatric Regenerative Medicine, Stanford University School of Medicine, Stanford, California, USA.
Derrick C WanHagey Laboratory for Pediatric Regenerative Medicine, Stanford University School of Medicine, Stanford, California, USA.ORCID 0000-0003-4666-1683

Funding

Center for Dental, Oral & Craniofacial Tissue & Organ Regeneration U24DE026914
6 · The paper itself

Abstract

Radiation-induced peripheral neuropathy (RIPN) is a devastating sequela of radiation therapy (XRT). Current treatment options are limited. Deferoxamine (DFO) has been useful in treating radiation-induced dermal fibrosis. This study aimed to evaluate DFO for RIPN. Thus, 18 mice received 30Gy of fractionated XRT. After a fibrosis development interval, mice were treated with DFO injections, saline injections (Saline) or none (IR) (n = 6 per group). Longitudinal measures included footprint analysis, cold allodynia testing and monofilament testing. Immunofluorescent staining for myelination (MPZ) and axonal regeneration (GAP43) took place at the conclusion of the experiment. DFO improved motor deficits (Combined Toe Spread scores: -9.72, -12.91, -12.72 for DFO, Saline and IR, respectively). Additionally, DFO improved cold allodynia (duration ratios: 0.90, 0.70 and 0.73 for DFO, Saline and IR, respectively). Monofilament testing revealed the same trend, though not statistically significant. Additionally, DFO increased remyelination on MPZ staining (normalized myelin ratios: 0.84 DFO, 0.74 Saline, 0.72 IR) and increased axonal regeneration on GAP43 staining compared to all groups (pixel area: 3.76% DFO, 1.95% Saline, 1.94% IR, 2.09% Control). In conclusion, this murine study revealed DFO improves RIPN sensorimotor function. This is encouraging as disease-modifying treatments are limited for patients suffering from this XRT side effect.

Indexed as

DeferoxaminePeripheral Nervous System DiseasesRadiation InjuriesAnimalsAxonsHyperalgesiaMaleMiceMyelin SheathNerve RegenerationDeferoxaminedemyelinationferroptosisfibrosisnerve injuryperipheral nerveradiationradiotherapyreactive oxygen speciesregeneration

Identifiers

PMID42252579
PMCPMC13243696

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.